199 related articles for article (PubMed ID: 17594526)
21. [A pilot project with mammography--results from the first screening round].
Wang H; Hofvind SS; Thoresen SØ
Tidsskr Nor Laegeforen; 2000 Nov; 120(27):3237-40. PubMed ID: 11187160
[TBL] [Abstract][Full Text] [Related]
22. [Incidence of breast cancer before and after implementation of mammography screening].
Hofvind S; Sørum R; Haldorsen T; Langmark F
Tidsskr Nor Laegeforen; 2006 Nov; 126(22):2935-8. PubMed ID: 17117191
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening?
Hofvind S; Sakshaug S; Ursin G; Graff-Iversen S
Int J Cancer; 2012 Jun; 130(12):2930-8. PubMed ID: 21732346
[TBL] [Abstract][Full Text] [Related]
24. No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study.
Lund E; Nakamura A; Thalabard JC
Eur J Cancer; 2018 Jan; 89():102-112. PubMed ID: 29245077
[TBL] [Abstract][Full Text] [Related]
25. Update of the Swedish two-county program of mammographic screening for breast cancer.
Tabàr L; Fagerberg G; Duffy SW; Day NE; Gad A; Gröntoft O
Radiol Clin North Am; 1992 Jan; 30(1):187-210. PubMed ID: 1732926
[TBL] [Abstract][Full Text] [Related]
26. Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program.
Hofvind S; Skaane P; Vitak B; Wang H; Thoresen S; Eriksen L; Bjørndal H; Braaten A; Bjurstam N
Radiology; 2005 Nov; 237(2):437-43. PubMed ID: 16244251
[TBL] [Abstract][Full Text] [Related]
27. Seventeen-years overview of breast cancer inside and outside screening in Denmark.
Domingo L; Jacobsen KK; von Euler-Chelpin M; Vejborg I; Schwartz W; Sala M; Lynge E
Acta Oncol; 2013 Jan; 52(1):48-56. PubMed ID: 22943386
[TBL] [Abstract][Full Text] [Related]
28. Outcome analysis for women undergoing annual versus biennial screening mammography: a review of 24,211 examinations.
Hunt KA; Rosen EL; Sickles EA
AJR Am J Roentgenol; 1999 Aug; 173(2):285-9. PubMed ID: 10430120
[TBL] [Abstract][Full Text] [Related]
29. Digital mammography screening: average glandular dose and first performance parameters.
Weigel S; Girnus R; Czwoydzinski J; Decker T; Spital S; Heindel W
Rofo; 2007 Sep; 179(9):892-5. PubMed ID: 17705112
[TBL] [Abstract][Full Text] [Related]
30. Comparison of screening mammography in the United States and the United kingdom.
Smith-Bindman R; Chu PW; Miglioretti DL; Sickles EA; Blanks R; Ballard-Barbash R; Bobo JK; Lee NC; Wallis MG; Patnick J; Kerlikowske K
JAMA; 2003 Oct; 290(16):2129-37. PubMed ID: 14570948
[TBL] [Abstract][Full Text] [Related]
31. Screening behaviors and long-term compliance with mammography guidelines in a breast cancer screening program.
Weinberg AD; Cooper HP; Lane M; Kripalani S
Am J Prev Med; 1997; 13(1):29-35. PubMed ID: 9037339
[TBL] [Abstract][Full Text] [Related]
32. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
33. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators.
Otten JD; Karssemeijer N; Hendriks JH; Groenewoud JH; Fracheboud J; Verbeek AL; de Koning HJ; Holland R
J Natl Cancer Inst; 2005 May; 97(10):748-54. PubMed ID: 15900044
[TBL] [Abstract][Full Text] [Related]
34. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program.
Hofvind S; Thoresen S; Tretli S
Cancer; 2004 Oct; 101(7):1501-7. PubMed ID: 15378474
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer screening--the European experience.
Perry NM
Int J Fertil Womens Med; 2004; 49(5):228-30. PubMed ID: 15633481
[TBL] [Abstract][Full Text] [Related]
36. Screening mammography after breast cancer treatment: patterns in community practice.
Krishnaraj A; Yankaskas BC; Stearns SC
Breast Cancer Res Treat; 2006 May; 97(1):73-80. PubMed ID: 16331348
[TBL] [Abstract][Full Text] [Related]
37. St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
Falck AK; Röme A; Fernö M; Olsson H; Chebil G; Bendahl PO; Rydén L
Br J Surg; 2016 Apr; 103(5):513-23. PubMed ID: 26856820
[TBL] [Abstract][Full Text] [Related]
38. [Nationwide breast cancer screening fully accomplished; results from the implementation phase 1990-1997. National Evaluation Team for Breast Cancer Screening].
Ned Tijdschr Geneeskd; 2000 Jun; 144(23):1124-9. PubMed ID: 10876708
[TBL] [Abstract][Full Text] [Related]
39. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results.
Weedon-Fekjaer H; Vatten LJ; Aalen OO; Lindqvist B; Tretli S
J Med Screen; 2005; 12(4):172-8. PubMed ID: 16417693
[TBL] [Abstract][Full Text] [Related]
40. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
